XLO

Xilio Therapeutics Inc
3.03
-0.05 (-1.62%)
Company Name Stock Ticker Symbol Market Type
Xilio Therapeutics Inc XLO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -1.62% 3.03 18:25:02
Open Price Low Price High Price Close Price Prev Close
3.07 2.925 3.24 3.03 3.08
more quote information »

Recent News

Date Time Source Heading
3/02/202317:03EDGARSecurities Registration: Employee Benefit Plan (s-8)
3/02/202316:05GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
2/27/202307:30GLOBEXilio Therapeutics to Present at Upcoming Investor..
2/16/202307:30GLOBEXilio Therapeutics to Present at the Citi 2023 Virtual..
2/09/202308:16EDGARAmended Statement of Ownership (sc 13g/a)
2/02/202307:30GLOBEXilio Therapeutics to Present at the Guggenheim Healthcare..
1/25/202316:02EDGARStatement of Ownership (sc 13g)
1/09/202308:32EDGARCurrent Report Filing (8-k)
12/23/202216:31EDGARCurrent Report Filing (8-k)
11/23/202207:30GLOBEXilio Therapeutics to Host Live Virtual Program Spotlighting..
11/21/202206:03EDGARNotice of Effectiveness (effect)
11/16/202216:17EDGARInitial Statement of Beneficial Ownership (3)
11/09/202216:17EDGARSecurities Registration Statement (simplified Form) (s-3)
11/09/202207:51EDGARQuarterly Report (10-q)
11/09/202207:47EDGARCurrent Report Filing (8-k)
11/09/202207:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
11/04/202207:30GLOBEXilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’..
9/22/202216:05GLOBEXilio Therapeutics to Present at Guggenheim Nantucket..
9/16/202216:51EDGARInitial Statement of Beneficial Ownership (3)
9/16/202216:16EDGARStatement of Changes in Beneficial Ownership (4)
9/15/202216:16EDGARCurrent Report Filing (8-k)
9/15/202216:05GLOBEXilio Therapeutics Appoints Tomas J. Heyman to Board of..
9/06/202216:05GLOBEXilio Therapeutics to Present at Morgan Stanley 20th Annual..
8/09/202207:48EDGARQuarterly Report (10-q)
8/09/202207:37EDGARCurrent Report Filing (8-k)
8/09/202207:30GLOBEXilio Therapeutics Announces Encouraging Preliminary Phase 1..
6/23/202219:31EDGARAmended Statement of Changes in Beneficial Ownership (4/a)
6/17/202216:32EDGARStatement of Changes in Beneficial Ownership (4)
6/17/202216:32EDGARStatement of Changes in Beneficial Ownership (4)
6/17/202216:32EDGARStatement of Changes in Beneficial Ownership (4)
6/17/202216:32EDGARStatement of Changes in Beneficial Ownership (4)
6/17/202216:07EDGARInitial Statement of Beneficial Ownership (3)
6/16/202207:30GLOBEXilio Therapeutics Announces Promotion of Martin Huber,..
6/13/202216:31EDGARCurrent Report Filing (8-k)
5/18/202207:30GLOBEXilio Therapeutics to Present at the H.C. Wainwright Global..
5/17/202207:30GLOBEXilio Therapeutics Appoints Stacey Davis as Chief Business..
5/12/202207:41EDGARQuarterly Report (10-q)
5/12/202207:38EDGARCurrent Report Filing (8-k)
5/12/202207:30GLOBEXilio Therapeutics Reports Pipeline and Business Highlights..
4/26/202216:12EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
4/26/202216:07EDGARProxy Statement (definitive) (def 14a)
4/07/202206:30GLOBEXilio Therapeutics to Present at the 21st Annual Needham..